Genmab Announces Net Sales of DARZALEX® (daratumumab) for 2024

Company Overview - Genmab is an international biotechnology company headquartered in Copenhagen, Denmark, with a presence across North America, Europe, and Asia Pacific [3] - The company focuses on developing innovative and differentiated antibody therapeutics to improve the lives of patients with cancer and other serious diseases [2] - Genmab has a proprietary pipeline that includes bispecific T-cell engagers, antibody-drug conjugates, next-generation immune checkpoint modulators, and effector function-enhanced antibodies [2] - By 2030, the company aims to transform patient lives with its KYSO (knock-your-socks-off) antibody medicines [2] Product Performance - Worldwide net trade sales of DARZALEX (daratumumab) in 2024 totaled USD 11,670 million, including USD 6,588 million in the U S and USD 5,082 million in the rest of the world [1] - The sales include both the intravenous product and the subcutaneous (SC) product, sold under the tradename DARZALEX FASPRO in the U S [1] - Genmab receives royalties on the worldwide net sales of DARZALEX under an exclusive license agreement with Johnson & Johnson (J&J) [1][5] Business Model - Genmab operates under a royalty-based model for DARZALEX, leveraging J&J's global development, manufacturing, and commercialization capabilities [1] - The company owns several trademarks, including Genmab, HuMax, DuoBody, HexaBody, DuoHexaBody, HexElect, and KYSO, while DARZALEX and DARZALEX FASPRO are trademarks of Johnson & Johnson [5]